Left to right: John Moult, Judith Guenther, Okexandr Isayev
Can computational chemistry predict medicine-like molecules for any protein?
Maybe, but despite the ability of machine learning to identify such promising compounds, finding a reliable algorithm to select, design and rank these molecules remains a daunting challenge.
Frankfurt, February 26, 2024– The Structural Genomics Consortium (SGC) at Goethe University Frankfurt am Main has secured a significant €11.8 million in funding from the German Cancer Aid for the development of new, targeted cancer drugs, with a particular emphasis on rare tumor diseases.
The Structural Genomics Consortium at University College London (SGC-UCL) is led by Prof Matthew Todd. The group’s research is focused on the design and chemical synthesis of new small molecule protein binders towards medicines that improve human health.
The Structural Genomics Consortium at The Neuro (SGC Neuro) focuses on the “Dark Genome” targets, under-studied genes implicated in neurodegenerative disorders, and creating tools such as brain cells differentiated from genetically modified induced pluripotent stem cell lines and commercial antibody profiling through the
The Structural Genomics Consortium at the Goethe University Frankfurt (SGC-Frankfurt) is focused on the development and rational design of selective inhibitors (chemical probes) targeting key signalling molecules and their use for the validation of new targets.
More specifically the research team focuses on three main key areas:
The Structural Genomics Consortium at the Karolinska Institutet (SGC Karolinska) is interested in studying inflammation and autoimmune diseases based on inflammatory processes, including inflammatory bowel diseases, neuroinflammation and liver fibrosis.
More specifically the research team focuses on three scientific areas:
The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC) is a team of scientists dedicated to discovering and sharing selective, small-molecule chemical probes of the dark proteome. Their work aims to facilitate the discovery of new molecular targets for drug discovery and help speed the creation of new medicines for patients.
The main SGC-UNC research programs include:
The Structural Genomics Consortium at the University of Toronto (SGC-Toronto) collaborates widely locally and globally to support breakthrough research - creating protein-focused open science tools, knowledge, and reagents to enable drug discovery. The SGC-Toronto has a team of more than 50 trainees, researchers and support staff working in approximately 14,000 square feet of research space on discovery projects in the areas of chemical probes, structural biology, bioinformatics, molecular biophysics, cellular assays, and chemical biology and target discovery.
Victoria received her PhD from the University of Toronto, Canada. Her grad studies focused on the effects of natural variation in genetic backgrounds on perturbed phenotypes using C. elegans as a model organism. Victoria’s work is focusing on the development of cellular assays for E3 ligases.
Corentin Bedart graduated with a PhD in the field of biomolecules, pharmacology, and therapeutics, specializing in computational chemistry and in silico drug discovery, from the University of Lille (France) in December 2021. He also graduated with a PharmD degree from the Faculty of Pharmaceutical and Biological Sciences at the University of Lille (France) in September 2020. He joined the SGC Research Informatics group in September 2022 to participate in the development and testing of an informatics platform for a pan-Canadian drug discovery chemical library.